Moves at FDA, NIH

Monica Bertagnolli and Kimryn Rathmell are stepping down as the seventeenth directors of the National Institutes of Health and the National Cancer Institute, respectively. Bertagnolli worked with the Biden Administration on the White House initiative on women’s health research, under which NIH has committed $200 million in fiscal year 2025 research awards. Rathmell, among other actions, launched an initiative to identify underlying biological, social and environmental factors causing the rise in early onset cancer.

Jacqueline Corrigan-Curay has become acting head of FDA’s CDER, following the departure of Patrizia Cavazzoni. Corrigan-Curay has been director of the agency’s office of medical policy since 2016.  Cavazzoni’s departure, along with that of several other top FDA officials, paves the way for incoming President Donald Trump to reshape the agency...